Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan.

ABSTRACT:

Introduction

Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Information is lacking regarding real-world testing patterns.

Methods

This descriptive, retrospective observational study used the Japan Medical Data Vision Co., Ltd. (MDV), database (June 2017-November 2018) and covered data for EGFR, ALK, ROS1, and PD-L1; records on BRAF testing were not yet available. Adults diagnosed with having lung cancer (International Classification of Diseases-10 C34) with record of any biomarker test ordered were included.

Results

Of 8323 patients with

SUBMITTER: Yatabe Y 

PROVIDER: S-EPMC8474388 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature